IMRN News and Press, Immuron Limited From 12/23/22

Australian biotech Immuron Limited ( NASDAQ: IMRN ) gained ~47% pre-market Friday after announcing that the FDA greenlighted its Investigational New Drug (IND) application to study OTC medicine Travelan as a treatment to prevent infectious diarrhea. Accordingly, Immuron ( IMRN ...

Highlights: Immuron receives U.S. Food and Drug administration (FDA) approval for Travelan Investigational New Drug (IND) application IND to evaluate the efficacy of a single dose of Travelan to prevent infectious diarrhea caused by ETEC is now active Pla...

Highlights: Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA) Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the USA Clinical Trial to examine a dosing regimen for Travelan more suited f...

Highlights: Immuron has completed settlement of strategic investment in leading gut health biotech Ateria Health, in accordance with signed subscription and option agreement (announced 13 October 2022): Strategic investment of approximately £1.5m (A$2.6m) to a...

MELBOURNE, Australia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases; i...

Australia's Immuron ( NASDAQ: IMRN ) said it is acquiring 17.5% stake in U.K. based Ateria Health by investing ~£1.5M. Immuron has been offered one board seat at Ateria after the transaction is complete. Immuron has an option to invest a...

Highlights: Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health: Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of Ateria Health; Option for further investment of £...

Highlights: Clinical Trial Master Service Agreement with US-based Pharmaron Executed Investigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA) Plans in place to initiate a Controlled Human Infection Model (CHI...

The following slide deck was published by Immuron Limited in conjunction with their 2022 Q4 earnings call. For further details see: Immuron Limited 2022 Q4 - Results - Earnings Call Presentation

Immuron Limited (IMRN) Q4 2022 Earnings Conference Call September 6, 2022, 7:00 PM ET Company Participants Steven Lydeamore - Chief Executive Officer Conference Call Participants Presentation Unidentified Company Representative Good morning, e...